Physician Views Preview: Assessing Eli Lilly’s tirzepatide in type 2 diabetes

A notable highlight of the recent virtually-held American Diabetes Association (ADA) annual scientific meeting was the presentation of detailed results for Eli Lilly’s novel GIP/GLP-1 receptor agonist tirzepatide from the extensive Phase III SURPASS clinical study programme.

Previously disclosed top-line results are impressive and our physician survey-based research suggests that tirzepatide could be a game-changing new treatment option for type 2 diabetes.

See FirstImpact Results – Three reasons why tirzepatide will be a game-changer in diabetes

With more detailed clinical data under the spotlight at ADA, we decided a run a follow-up snap-poll to European and US based endocrinologists asking the following questions…

Based on available clinical data, do you think tirzepatide is a potentially treatment paradigm-changing therapy for type 2 diabetes?

Do you agree that the efficacy demonstrated by tirzepatide, such as c.50% of patients reaching an A1c < 5.7% or c.30-40% of patients (depending on the trial) losing >15% of their body weight over 40-52 weeks will likely transform how physicians think about treating their patients with diabetes and what are reasonable goals to treatment?

What is the most compelling thing about tirzepatide as a potentially novel treatment option for type 2 diabetes?

What concerns you most about using tirzepatide/what factor would you anticipate preventing you from adopting it more readily if approved and launched?

Once approved how would you anticipate adopting tirzepatide, assuming that you face no/minimal barriers to treatment access?

Survey results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here

To read more Physician Views articles, click here.